Table 2. Treatment to the target by drugs.
| Achieved lipid level (mg/dL) | N, % | LDL-C<100 | TC<160 | TG<150 | HDL-C≥40/50 |
|---|---|---|---|---|---|
| No lipid lowering drugs | 1052, 30.2% | 44.96% | 31.75% | 71.01% | 51.43% |
| With lipid lowering drugs | 2434, 69.8% | ||||
| Monotherapy | 2185, 89.8% | ||||
| Statin | 2040 | 58.82% | 44.31% | 69.71% | 52.55% |
| Fibrate | 131 | 50.38% | 25.95% | 25.95% | 25.19% |
| Ezetimibe or Cholestyramine (E or C) | 13 | 23.08% | 15.38% | 61.54% | 53.85% |
| Nicotinic acid (N) | 1 | 0% | 0% | 0% | 0% |
| Two-combined therapy | 241, 9.9% | ||||
| Statin + Fibrate | 63 | 65.08% | 36.51% | 41.27% | 31.75% |
| Statin + E or C | 168 | 51.79% | 39.88% | 63.10% | 58.93% |
| Statin + N | 6 | 83.33% | 16.67% | 16.67% | 0% |
| Fibrate + E or C | 3 | 66.67% | 33.33% | 33.33% | 66.67% |
| Fibrate + N | 1 | 100% | 0% | 0% | 0% |
| Three-combined therapy | 8, 0.3% | ||||
| Statin + Fibrate + E or C | 8 | 50% | 0% | 12.50% | 25.00% |
TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride.